4.2.4.2. pharmacological management. 4.2.4.2.1. oestrogen oestrogenic drugs including conjugated equine oestrogens, oestradiol, tibolone raloxifene, used hormone replacement therapy (hrt) women natural therapeutic menopause. oestrogen treatment sui tested using oral, transdermal, vaginal routes administration. available evidence suggests vaginal oestrogen treatment oestradiol oestriol associated increased risk thromboembolism, endometrial hypertrophy, breast cancer seen systemic administration [236-238]. vaginal (local) treatment primarily used treat symptoms vaginal atrophy postmenopausal women. cochrane sr looked use oestrogen therapy postmenopausal women given local oestrogen therapy seventeen studies focused sui . also narrative review oestrogen therapy urogenital diseases . cochrane review found vaginal oestrogen treatment improved symptoms sui short term . small, low-quality trials comparing vaginal oestrogen treatment phenylpropanolamine, pfmt, es use adjunct surgery sui. local oestrogen less likely improve ui pfmt differences ui outcomes observed comparisons. single trial local oestrogen therapy comparing ring device pessaries found difference ui outcomes, although women preferred ring device. one trial, significant adverse effects following vaginal administration oestradiol vulvovaginal atrophy two year period reported . vaginal oestrogen therapy given conjugated equine oestrogen, oestriol oestradiol vaginal pessaries, vaginal rings, creams. ideal treatment duration long-term effects uncertain. review local oestrogen treatment showed improvement ui placebo vaginal rings, favoured subjectively pessaries . one rct postmenopausal women showed benefit adding intravaginal oestriol vaginal es pfmt female sui . studies systemic hrt non-urogenital primary outcomes looked change urinary continence secondary analyses. large trials using conjugated equine oestrogens showed higher rate development worsening ui compared placebo sui improvement [341-346]. single rct, use raloxifene associated development worsening ui . two small rcts using oral oestriol oestradiol hrt vulvovaginal atrophy suggested ui symptoms improved although evidence unclear . 4.2.4.2.1.1. summary evidence recommendations oestrogens summary evidencelevaginal oestrogen therapy improves sui postmenopausal women short term.1aneoadjuvant adjuvant use local oestrogens ineffective adjunct surgery sui.2bsystemic hrt using conjugated equine oestrogens improve sui may worsenpre-existing ui.1a recommendationsstrength ratingoffer vaginal oestrogen therapy postmenopausal women stress urinary incontinence (sui) symptoms vulvovaginal atrophy.strongin women taking oral conjugated equine oestrogen hormone replacement therapy (hrt) develop experience worsening sui, discuss alternative hrt.strong 4.2.4.2.2. duloxetine duloxetine inhibits presynaptic reuptake neurotransmitters, serotonin (5-hydroxytryptamine; 5-ht) noradrenaline (ne). sacral spinal cord, increased concentration 5-ht ne synaptic cleft increases stimulation 5-ht ne receptors pudendal motor neurons, turn increases resting tone contraction strength urethral striated sphincter. duloxetine evaluated treatment female sui mui three srs . improvement ui compared placebo observed clear differences sui mui. one study reported cure ui 10% patients. improvement ui qol questionnaire found study, used primary endpoint. study comparing duloxetine, 80 mg daily, pfmt alone,pfmt + duloxetine, placebo , duloxetine reduced leakage compared pfmt treatment. global improvement qol better combined therapy treatment. significant difference pfmt treatment trial. two open-label studies follow-up > 1 year evaluated long-term effect duloxetine controlling sui . studies high patient withdrawal rate, due lack efficacy high incidence adverse events, including nausea vomiting (> 40% patients), dry mouth, constipation, dizziness, insomnia, somnolence, fatigue. sr showed significant efficacy duloxetine compared placebo women sui, increased risk adverse events . adverse effects duloxetine include mental health problems suicidal ideation. meta-analysis four rcts including 1,910 women sui reported suicidality, violence, akathisia events, suggested discontinuation rate due adverse events around one seven harm may outweigh benefit treatment . meta-analysis twelve placebo-controlled trials involving almost 3,000 patients showed patients major depressive disorders significant differences incidence suicide-related events duloxetine vs. placebo . 4.2.4.2.2.1. summary evidence recommendations duloxetine summary evidenceleduloxetine improves sui women, chances cure low.1aduloxetine may cause significant gastrointestinal central nervous system adverse effects, leading high rate treatment discontinuation, although symptoms may limited first weeks treatment.1a recommendationsstrength ratingoffer duloxetine (where licensed) selected patients stress urinary incontinence unresponsive conservative treatments want avoid invasive treatment, counselling carefully risk adverse events.strongduloxetine initiated withdrawn using dose titration high risk adverse events.strong 4.2.4.2.3. adrenergic agonists cochrane sr including 22 rcts involving 673 women seven different adrenergic drugs (phenylpropanolamine eleven trials, midodrine two, norepinephrine three, clenbuterol another three, terbutaline one, eskornade one ro 115-1240 one) found weak evidence adrenergic agonists may improve sui. moreover, side effects occur usually minor. evidence needed compare adrenergic drugs drugs sui and, also pfmt .